Oncology Town Hall: From Evidence to Action—Applying KRAS-Targeted Advances in Solid Tumors

Activity Overview

This online, on-demand virtual symposium brings together renowned experts in KRAS mutations in solid tumors. In this educational program, these experts discuss key KRAS-related data presented at the 2026 ASCO Annual Meeting. Using a dynamic format that combines abstract presentations with expert faculty discussion, the program places emerging evidence into clinical context and explores its practical implications for treatment selection, toxicity management, and multidisciplinary care across multiple KRAS-mutated solid tumors. This approach helps clinicians translate new research findings into evidence-based strategies that can improve patient outcomes in everyday practice.

This educational activity is an archive of the live symposium held on July 30, 2026.

Target Audience

This educational activity is directed toward academic and community-based oncologists, pathologists, advanced practice providers, oncology nurses, and other health care providers involved in treating patients with KRAS/RAS-mutated cancers.

Learning Objectives

Upon successful completion of this activity, you should be better prepared to:

• Evaluate the role of KRAS/RAS mutations across solid tumors and their implications for biomarker testing
• Assess efficacy and safety profiles of approved and emerging KRAS/RAS-targeted therapies in solid tumors
• Implement evidence-based strategies to prevent, monitor, and manage adverse events associated with KRAS/RAS-targeted therapies

The staff of Physicians’ Education Resource^®, LLC have no relevant financial relationships with ineligible companies.

PER^® mitigated all conflicts of interest for faculty, staff, and planners prior to the start of this activity by using a multistep process.

Off-Label Disclosure and Disclaimer

This accredited continuing education activity was planned in accordance with the ACCME Standards for Integrity and Independence to ensure balance, objectivity, independence, and scientific rigor. Faculty were instructed to use generic names when possible and to base recommendations on the best available evidence. Proprietary product names may be referenced in clinical discussion for educational purposes only and do not imply endorsement.

This activity may include discussion of investigational, unapproved, or off‑label uses of drugs or devices. Learners are advised to consult prescribing information for products discussed. Content is provided for educational purposes only and is not a substitute for the independent clinical judgment of a health care professional. Learners are encouraged to critically evaluate the information presented and apply their own clinical judgment.

The views expressed are those of the individual faculty members and do not necessarily reflect the views of the accredited provider or any entity providing commercial support.

This activity may have used AI-assisted tools to support educational development. All content was reviewed and approved by qualified faculty or planners. The accredited provider retains full responsibility for accuracy, balance, and independence.